Maia Biotechnology Stock Investor Sentiment

MAIA Stock  USD 1.88  0.02  1.08%   
About 53% of MAIA Biotechnology's investor base is interested to short. The analysis of the overall investor sentiment regarding MAIA Biotechnology suggests that many traders are impartial. The current market sentiment, together with MAIA Biotechnology's historical and current headlines, can help investors time the market. In addition, many technical investors use MAIA Biotechnology stock news signals to limit their universe of possible portfolio assets.
  

MAIA Biotechnology Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards MAIA Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three weeks ago at finance.yahoo.com         
MAIA Biotechnology to Present at Biotech Showcase 2025
Yahoo News
over three weeks ago at news.google.com         
MAIA Biotechnology enters clinical supply agreement with BeiGene for THIO - TipRanks
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Theagene Jean-manasse of 10225 shares of MAIA Biotechnology at 1.98 subject to Rule 1...
Macroaxis News
over a month ago at finance.yahoo.com         
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
Yahoo News
over a month ago at news.google.com         
MAIA soars after its cancer drug receives FDA rare pediatric disease designation - Kursiv Media
Google News at Macroaxis
over a month ago at finance.yahoo.com         
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediat...
Yahoo News
over a month ago at www.macroaxis.com         
Acquisition by Guerrero Ramiro of 53418 shares of MAIA Biotechnology at 2.08 subject to Rule 16b-3
Macroaxis News
over a month ago at seekingalpha.com         
MAIA Biotechnology announces 950,000 private placement
seekingalpha News
over a month ago at finance.yahoo.com         
MAIA Biotechnology Announces Private Placement of Approximately 950,000
Yahoo News
over two months ago at finance.yahoo.com         
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial...
Yahoo News
over two months ago at www.macroaxis.com         
Acquisition by Chaouki Steven M of 34641 shares of MAIA Biotechnology at 1.17 subject to Rule 16b-3
Macroaxis News
over two months ago at news.google.com         
Analysts Set Expectations for MAIA Biotechnology Q1 Earnings - MarketBeat
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Vitoc Vlad of 19982 shares of MAIA Biotechnology at 1.8 subject to Rule 16b-3
Macroaxis News
over two months ago at news.google.com         
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem...
Google News at Macroaxis
over two months ago at news.google.com         
MAIA Biotechnology Reveals Promising Phase 2 Trial Results - TipRanks
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about MAIA Biotechnology that are available to investors today. That information is available publicly through MAIA media outlets and privately through word of mouth or via MAIA internal channels. However, regardless of the origin, that massive amount of MAIA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MAIA Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MAIA Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MAIA Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MAIA Biotechnology alpha.

MAIA Biotechnology Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Maia Biotechnology director Steven Chaouki buys 55,553 in shares
11/04/2024
2
Director Steven Chaouki Acquires 22,133 Shares of MAIA Biotechnology Inc
11/05/2024
3
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
11/07/2024
4
Acquisition by Vitoc Vlad of 19982 shares of MAIA Biotechnology at 1.8 subject to Rule 16b-3
11/15/2024
5
Acquisition by Chaouki Steven M of 34641 shares of MAIA Biotechnology at 1.17 subject to Rule 16b-3
11/27/2024
6
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
12/03/2024
7
Acquisition by Guerrero Ramiro of 53418 shares of MAIA Biotechnology at 2.08 subject to Rule 16b-3
12/13/2024
8
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
12/19/2024
9
Acquisition by Theagene Jean-manasse of 10225 shares of MAIA Biotechnology at 1.98 subject to Rule 16b-3
12/31/2024
10
MAIA Biotechnology to Present at Biotech Showcase 2025
01/10/2025

Complementary Tools for MAIA Stock analysis

When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Money Managers
Screen money managers from public funds and ETFs managed around the world
Fundamental Analysis
View fundamental data based on most recent published financial statements
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals